Real-world Access to T cell-directed Therapies in Multiple Myeloma: Driving Away Health Disparities
Tweetorial #2
Pre-assessment

Before you view this Tweetorial, please take this pre-assessment. Taking this pre-assessment does not immediately qualify learners to earn credit.

Certificates of credit will only be sent to learners who also receive a passing score on the post-test (separate from this survey), and fill out the evaluation form and application for credit.

Question Title

* 1. What are your credentials?

MD/DO

Trainee/Fellow

Nurse

Pharmacist

Other (please specify)

Question Title

* 2. What is your community of practice?

Academic

Community

Other (please specify)

Question Title

* 3. What is your specialty?

Hematology

Oncology

Pathology

Radiology

Other (please specify)

Question Title

* 4. Relative to White patients, which of the following is more likely to be observed in African American patients diagnosed with Myeloma?

Older age

High-risk cytogenetics

MGUS

Bone fractures

Question Title

* 5. Compared with White patients, Black patients with myeloma are more likely to experience which of the following?

Delayed diagnosis

Receipt of transplant

Receipt of CAR-T

Access to clinical trials

Question Title

* 6. Which of the following racial/ethnic groups has the highest rate of clinical trial ineligibility in multiple myeloma?

White people

Black people

Asian people

Hispanic or Latino people

Question Title

* 7. How many of the 4 U.S. state where more than 30% of the population is composed of Black people had open clinical trials for CART T-cell therapy or bispecific antibodies for myeloma?

Question Title

* 8. Please let us know who you are so we can connect your responses to your post-test & application to claim CME credit (completed after participating in the activity)

First & Last Name

State/Province

ZIP/Postal Code

Country

Email Address

Real-world Access to T cell-directed Therapies in Multiple Myeloma: Driving Away Health Disparities Tweetorial #2*Pre-assessment*

Question Title

* 1. What are your credentials?

Question Title

* 2. What is your community of practice?

Question Title

* 3. What is your specialty?

Question Title

* 4. Relative to White patients, which of the following is more likely to be observed in African American patients diagnosed with Myeloma?

Question Title

* 5. Compared with White patients, Black patients with myeloma are more likely to experience which of the following?

Question Title

* 6. Which of the following racial/ethnic groups has the highest rate of clinical trial ineligibility in multiple myeloma?

Question Title

* 7. How many of the 4 U.S. state where more than 30% of the population is composed of Black people had open clinical trials for CART T-cell therapy or bispecific antibodies for myeloma?

Question Title

* 8. Please let us know who you are so we can connect your responses to your post-test & application to claim CME credit (completed after participating in the activity)

Real-world Access to T cell-directed Therapies in Multiple Myeloma: Driving Away Health Disparities
Tweetorial #2
Pre-assessment